|By Marketwired .||
|June 19, 2014 09:30 AM EDT||
NEW YORK, NY -- (Marketwired) -- 06/19/14 -- Daxor Corporation (NYSE MKT: DXR) -- The Board of Directors of Daxor Corporation, at its June 18, 2014 meeting, renewed its annual stock buy-back program of up 250,000 shares.
The Board of Directors also voted to explore options for partnering with a much larger company to facilitate acceptance of its unique medical services and technology. The focus will be on a large company with experience in distribution and marketing. The company intends to engage an investment banker to expedite this process. As part of this process, the Board of Directors is also willing to consider a partial sale of the company.
The company remains committed to its fundamental goal of making its blood volume analyzer a standard of care in medical and surgical conditions. Daxor's BVA-100 is the only semi-automated instrument approved by the FDA for direct blood volume measurement.
Accurate knowledge of a patient's blood volume is essential to determining who should receive a transfusion and who should not receive a transfusion. For example, the President of Daxor, Dr. Joseph Feldschuh, fractured his hip on February 4, 2014 and had emergency surgery. He lost approximately 10 times as much blood as was estimated by the surgeon and anesthesiologist. The actual blood loss was documented by a subsequent blood volume measurement which demonstrated the true extent of the severe blood loss. Fortunately Dr. Feldschuh also had a unit of his own frozen blood available which had been collected four-and-a-half years previously and was administered shortly after the surgery when he experienced symptoms due to the blood loss.
Blood loss is just one example of where precise knowledge of a patient's blood volume is essential, but is unavailable in most hospitals in the United States. Congestive heart failure, the #1 expense for Medicare patients admitted to hospitals in the United States, is primarily a blood volume derangement. A study published from the Mayo Clinic in the Journal of the American College of Cardiology - Heart Failure documented that congestive heart failure patients are a specific group requiring significantly different modes of treatment depending on the underlying blood volume derangement. At the present time patients are not routinely treated utilizing blood volume measurements. The death rate for congestive heart failure patients is 30 to 40% within one year of hospitalization for heart failure.
Renal dialysis patients, patients with hypertension, syncopy patients (fainting), are common conditions where blood volume derangements are essential to understanding the pathology of the patients. Patients are routinely treated for these conditions on the basis of surrogate tests which have been shown to be inaccurate.
A fundamental goal of the company is to make blood volume measurement a standard of care so that patients are optimally treated, particularly in conditions with high death rates and permanent, severe complications.
The company has also pioneered the use of frozen autologous (self storage) blood. Such blood stored at super-low temperatures can be used for up 2 to 10 years after collection. The American Medical Association has stated that "the only safe blood is one's own blood." Despite the obvious benefits of such a program, this service has minimal utilization.
Additional information and analyst evaluation of Daxor is available on our website www.daxor.com.